Aegis Capital Corp. recently initiated coverage of ViewRay (NASDAQ: VRAY), issuing a ‘Buy’ rating and $11 price target on the company’s stock. ViewRay’s MRIdian® radiation therapy system is designed to address key restrictions of current external-beam radiation therapy technologies, and is the first of its kind to use real-time imaging that visibly defines the targeted tumor from the surrounding soft tissue and other critical organs. The company believes this will greatly improve the safety and efficacy of radiation therapy, leading to better results for patients. Most recently, the company announced that the Edogawa Hospital in Tokyo, Japan, purchased the system for use with its radiation oncology offerings.
To learn more, visit www.viewray.com
ViewRay®, Inc. (Nasdaq: VRAY) designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. The company believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.NetworkNewsWire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer